A novel organosulfur compound, thiacremonone, regulates RANKL-inducedosteoclast differentiation

Collection with item attached
2017
Item details URL
http://open-repository.kisti.re.kr/cube/handle/open_repository/473852.do
DOI
10.1039/c7ra02049j
Title
A novel organosulfur compound, thiacremonone, regulates RANKL-inducedosteoclast differentiation
Description
This study was supported by the National Research Foundation of Korea(NRF) grant funded by the Korea government (MEST) (MRC, 20080062275;2015R1D1A1A01059240).
abstract
The medicinal properties of functionally active organosulfur compounds have received great attention for applications in treating various diseases. Thiacremonone (2,4-dihydroxy-2,5-dimethyl-thiophene-3-one, THIA) is a novel organosulfur compound generated from high-temperature-high-pressure-treated garlic and has been reported to display pharmacological effects against various diseases. However, the role of THIA in bone resorbing cells was not reported. Herein, we have examined the pharmacological properties of THIA on osteoclast differentiation in primary cultured bone marrow macrophages (BMMs). Our results showed that THIA suppressed receptor activator of NF-kappa B ligand (RANKL)-induced gene expression (c-Fos and NF-ATc1) for osteoclast differentiation under no cytotoxicity condition. In addition, THIA significantly inhibited TRAP positive multinucleated osteoclasts and F-actin ring formation during RANKL-mediated osteoclastogenesis. However, in primary cultured calvarial pre-osteoblasts, THIA did not influence the cytotoxicity and osteoblast differentiation, as assessed from the alkaline phosphatase (ALP) activity and mineralized nodule formation. Our findings have suggested that THIA can be considered as a potential agent for the therapeutics of bone diseases such as osteoporosis, alveolar bone resorption, and osteoarthritis.
provenance
Made available in Cube on 2018-09-28T10:30:34Z (GMT). No. of bitstreams: 0
language
English
author
Park, Kyung-Ran
Kim, Ji-Youn
Hong, Jin Tae
Yun, Hyung-Mun
accessioned
2018-09-28T10:30:34Z
available
2018-09-28T10:30:34Z
issued
2017
citation
RSC ADVANCES(7): 49
issn
2046-2069
uri
http://open-repository.kisti.re.kr/cube/handle/open_repository/473852.do
Funder
교육부
Funding Program
BK21플러스사업(0.5)
Project ID
1345274047
Jurisdiction
Rep.of Korea
Project Name
Frontier Pharmacy Leaders
rights
openAccess
type
article


Files in This Item

There are no attached files.